ConcertAI
Company

Last deal

$150M

Amount

Series C

Stage

29.03.2022

Date

2

all rounds

$300M

Total amount

General

About Company
Concerto HealthAI uses artificial intelligence to help oncologists make informed treatment decisions for cancer patients.

Industry

Sector :

Subsector :

Also Known As

Acorn Research, Vector Oncology

founded date

01.01.2018

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Founded in 2017, Concerto HealthAI specializes in designing and delivering oncology research and data analytics. Their platform analyzes large datasets of clinical and genomic data to identify patterns and insights for personalized cancer treatment. They also conduct oncology health outcomes and clinical trial efficiency research, using custom patient surveys to evaluate existing treatments and develop new ones. Concerto HealthAI's integrated real-world data and AI-driven solutions aim to transform how insights are generated and accelerate therapeutic innovations for patients.
Contacts